StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
35
Publishing Date
2023 - 10 - 17
1
2023 - 06 - 02
1
2023 - 03 - 01
1
2023 - 01 - 19
1
2022 - 12 - 19
1
2022 - 12 - 13
1
2022 - 10 - 17
1
2022 - 09 - 11
1
2022 - 08 - 30
1
2022 - 08 - 23
1
2022 - 07 - 12
1
2022 - 05 - 31
1
2022 - 04 - 27
1
2022 - 04 - 18
1
2022 - 04 - 11
1
2022 - 02 - 14
1
2022 - 01 - 18
1
2021 - 12 - 09
1
2021 - 12 - 06
1
2021 - 12 - 01
1
2021 - 09 - 16
1
2021 - 09 - 13
1
2021 - 08 - 27
1
2021 - 07 - 30
1
2021 - 07 - 07
1
2021 - 06 - 17
1
2021 - 06 - 11
2
2021 - 06 - 01
1
2021 - 05 - 21
1
2021 - 05 - 12
1
2021 - 04 - 12
1
2021 - 04 - 08
1
2021 - 03 - 10
1
2020 - 12 - 01
1
Sector
Finance
1
Health technology
35
N/a
4
Tags
100
1
Alliances
2
Antibody
1
Asco
2
Biocanada
1
Biosimilar
2
Biotechnology
2
Blincyto
1
Brukinsa
6
Btc-01
1
Cancer
12
Candidate
1
Cell
1
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
11
Collaboration
2
Colorectal cancer
1
Covid
1
Dkn-01
3
Enroll
2
Europe
1
Ev
1
Expansion
2
Genetown
1
Her2
3
Her2+
2
Her2-
3
Imaging
1
Label
1
Leap
2
Leukemia
5
Lumakras
3
Lung
3
Lung cancer
2
Milestone
1
N/a
5
Pancreatic
1
Pharmaceutical
1
Pharmaceuticals
2
Phase 1
1
Phase 2
4
Phase 3
7
Plus
1
Positive
11
Presentation
1
Product-news
2
Psoriasis
1
Repatha
2
Research
1
Response
2
Results
9
Solid tumors
2
Soliris
1
Stelara
1
Study
2
Symposium
2
Therapeutics
3
Topline
7
Treatment
3
Trial
23
Entities
Amgen inc.
13
Beigene, ltd.
35
Chemocentryx, inc.
5
Hutchison china meditech limited
1
Jazz pharmaceuticals plc
2
Leap therapeutics, inc.
5
Morgan stanley
1
Zymeworks inc.
6
Symbols
ABB
72
ABBV
62
ABLZF
31
ALDX
38
ALNY
38
ALPMF
26
ALPMY
26
AMGN
25
ARQT
29
ARVL
26
ATHE
26
ATNM
28
AVXL
24
AZN
64
BGNE
35
BIVI
28
BMY
73
BTAI
26
CLNN
25
CLSD
24
CNHI
69
CYBN
26
CYTK
29
DVAX
28
ENLV
26
EXEL
28
FBIO
41
FDMT
24
FNCTF
91
GIC
38
GILD
48
GTES
25
HON
53
HZNP
46
ICLR
43
IMAB
34
IMMP
34
IMMX
26
INCY
49
JNJ
203
LLY
161
MBRX
34
MDT
25
MRK
72
NVO
42
NVS
34
NVSEF
24
OCGN
27
PDSB
25
PFE
61
PSTV
35
REGN
44
RGNX
29
SNY
311
SNYNF
246
SRNE
38
STAG
32
TAK
56
TGTX
27
TMO
48
Exchanges
Nasdaq
35
Nyse
7
Crawled Date
2023 - 10 - 17
1
2023 - 06 - 02
1
2023 - 03 - 01
1
2023 - 01 - 19
1
2022 - 12 - 19
1
2022 - 12 - 14
1
2022 - 10 - 17
1
2022 - 09 - 12
1
2022 - 08 - 30
1
2022 - 08 - 23
1
2022 - 07 - 12
1
2022 - 05 - 31
1
2022 - 04 - 27
1
2022 - 04 - 18
1
2022 - 04 - 11
1
2022 - 02 - 14
1
2022 - 01 - 19
1
2021 - 12 - 09
1
2021 - 12 - 06
1
2021 - 12 - 01
1
2021 - 09 - 16
1
2021 - 09 - 13
1
2021 - 08 - 27
1
2021 - 07 - 30
1
2021 - 07 - 07
1
2021 - 06 - 17
1
2021 - 06 - 11
2
2021 - 06 - 01
1
2021 - 05 - 21
1
2021 - 05 - 12
1
2021 - 04 - 12
1
2021 - 04 - 08
1
2021 - 03 - 10
1
2020 - 12 - 01
1
Crawled Time
00:00
2
01:00
2
05:00
1
11:00
4
12:00
5
12:39
1
13:00
3
13:15
1
14:00
3
14:30
1
15:00
1
16:00
1
17:00
1
20:00
1
21:00
3
22:00
2
22:01
1
23:00
2
Source
www.biospace.com
30
www.globenewswire.com
1
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
symbols :
Bgne
save search
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
Published:
2023-10-17
(Crawled : 21:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-24.72%
|
O:
-2.74%
H:
2.94%
C:
1.41%
lung
cancer
cell
trial
response
plus
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Published:
2023-06-02
(Crawled : 23:00)
- prnewswire.com
ZYME
|
$8.56
-1.72%
-1.75%
340K
|
Health Technology
|
Email alert
Add to watchlist
BEIGF
|
$14.29
-9.87%
2.1K
|
n/a
|
Email alert
Add to watchlist
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
Email alert
Add to watchlist
JAZZ
|
$109.685
0.79%
0.78%
380K
|
Health Technology
|
Email alert
Add to watchlist
asco
positive
pharmaceuticals
trial
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Published:
2023-03-01
(Crawled : 16:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-41.71%
|
O:
4.08%
H:
3.06%
C:
0.89%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
17.37%
|
O:
-0.56%
H:
2.63%
C:
2.53%
repatha
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Published:
2023-01-19
(Crawled : 13:00)
- biospace.com/
ZYME
|
$8.56
-1.72%
-1.75%
340K
|
Health Technology
|
-12.9%
|
O:
4.32%
H:
3.53%
C:
-7.21%
JAZZ
|
$109.685
0.79%
0.78%
380K
|
Health Technology
|
-29.73%
|
O:
1.86%
H:
0.0%
C:
-1.04%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-50.59%
|
O:
2.58%
H:
1.53%
C:
0.98%
pharmaceuticals
trial
her2-
her2
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Published:
2022-12-19
(Crawled : 13:00)
- biospace.com/
ZYME
|
$8.56
-1.72%
-1.75%
340K
|
Health Technology
|
34.83%
|
O:
27.86%
H:
1.69%
C:
-17.8%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-36.13%
|
O:
-1.95%
H:
0.99%
C:
0.04%
btc-01
topline
trial
positive
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Published:
2022-12-13
(Crawled : 01:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-35.91%
|
O:
2.79%
H:
1.42%
C:
-0.92%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
-1.76%
|
O:
1.9%
H:
0.23%
C:
-3.46%
blincyto
leukemia
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Published:
2022-10-17
(Crawled : 12:00)
- biospace.com/
LPTX
|
$3.24
0.94%
0.93%
89K
|
Health Technology
|
-63.52%
|
O:
-1.14%
H:
4.6%
C:
3.24%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-15.98%
|
O:
4.91%
H:
6.28%
C:
2.04%
dkn-01
treatment
therapeutics
leap
cancer
study
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published:
2022-09-11
(Crawled : 00:00)
- prnewswire.com
MS
|
News
0 d
|
$93.76
1.81%
0.12%
6.4M
|
Finance
|
2.94%
|
O:
0.6%
H:
1.16%
C:
0.17%
CCXI
|
News
|
$51.99
-0.04%
|
Health Technology
|
0.85%
|
O:
-0.16%
H:
0.16%
C:
0.06%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-23.3%
|
O:
-1.88%
H:
3.78%
C:
3.73%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
9.78%
|
O:
-3.91%
H:
1.55%
C:
-0.16%
lumakras
lung
trial
positive
cancer
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published:
2022-08-30
(Crawled : 21:00)
- prnewswire.com
CCXI
|
News
|
$51.99
-0.04%
|
Health Technology
|
1.78%
|
O:
0.12%
H:
0.16%
C:
-0.31%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-20.9%
|
O:
3.3%
H:
1.98%
C:
0.39%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
13.71%
|
O:
1.03%
H:
0.95%
C:
-0.53%
lumakras
lung
topline
trial
cancer
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
Published:
2022-08-23
(Crawled : 14:00)
- biospace.com/
CCXI
|
News
|
$51.99
-0.04%
|
Health Technology
|
1.94%
|
O:
-0.12%
H:
0.0%
C:
0.0%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-24.31%
|
O:
-0.57%
H:
1.88%
C:
0.59%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
10.13%
|
O:
-0.09%
H:
0.0%
C:
-0.9%
soliris
candidate
biosimilar
positive
results
study
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
Published:
2022-07-12
(Crawled : 21:00)
- biospace.com/
LPTX
|
$3.24
0.94%
0.93%
89K
|
Health Technology
|
-74.32%
|
O:
0.0%
H:
0.0%
C:
-8.8%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-26.03%
|
O:
-0.58%
H:
4.0%
C:
1.51%
dkn-01
trials
therapeutics
leap
cancer
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
Published:
2022-05-31
(Crawled : 17:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-2.25%
|
O:
4.16%
H:
3.44%
C:
-1.66%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
6.52%
|
O:
-0.1%
H:
0.89%
C:
0.68%
topline
positive
phase 2
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
Published:
2022-04-27
(Crawled : 14:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-14.18%
|
O:
1.64%
H:
6.35%
C:
1.76%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
8.82%
|
O:
-0.33%
H:
1.2%
C:
-0.1%
repatha
label
results
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published:
2022-04-18
(Crawled : 22:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-28.2%
|
O:
-1.9%
H:
0.12%
C:
-3.78%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
7.04%
|
O:
-0.46%
H:
0.0%
C:
0.0%
stelara
biosimilar
positive
results
phase 3
topline
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
Published:
2022-04-11
(Crawled : 11:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-33.39%
|
O:
-2.56%
H:
0.15%
C:
-3.72%
brukinsa
leukemia
trial
response
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published:
2022-02-14
(Crawled : 23:00)
- prnewswire.com
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-36.22%
|
O:
4.23%
H:
6.03%
C:
2.76%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
21.24%
|
O:
0.33%
H:
0.52%
C:
-0.47%
lumakras
trial
100
cancer
pancreatic
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
Published:
2022-01-18
(Crawled : 00:00)
- biospace.com/
LPTX
|
$3.24
0.94%
0.93%
89K
|
Health Technology
|
13.03%
|
O:
-4.23%
H:
0.0%
C:
0.0%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-45.13%
|
O:
-2.98%
H:
0.0%
C:
0.0%
dkn-01
symposium
therapeutics
asco
positive
cancer
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Published:
2021-12-09
(Crawled : 14:30)
- biospace.com/
ZYME
|
$8.56
-1.72%
-1.75%
340K
|
Health Technology
|
-54.04%
|
O:
-1.06%
H:
1.33%
C:
-14.03%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-58.44%
|
O:
1.58%
H:
1.7%
C:
-4.5%
expansion
trial
collaboration
milestone
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
Published:
2021-12-06
(Crawled : 01:00)
- globenewswire.com
HCM
|
$18.2
7.44%
6.92%
120K
|
Health Technology
|
-48.13%
|
O:
-7.75%
H:
0.0%
C:
0.0%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-62.69%
|
O:
-11.5%
H:
0.0%
C:
0.0%
trial
cancer
colorectal cancer
enroll
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published:
2021-12-01
(Crawled : 22:00)
- biospace.com/
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-61.77%
|
O:
3.7%
H:
3.74%
C:
-0.91%
AMGN
|
News
|
$273.69
0.66%
0.65%
2.5M
|
Health Technology
|
36.72%
|
O:
0.78%
H:
2.59%
C:
0.18%
psoriasis
positive
results
phase 3
topline
← Previous
1
2
Next →
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.